Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
ConditionGlaucoma
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorGlaukos Corporation
About this trial
Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
Eligibility criteria
Qualifiers
Diagnosis of Ocular Hypertension or Open-Angle Glaucoma in the study eye
Disqualifiers
Prior incisional glaucoma surgery in the study eye
Prior argon laser trabeculoplasty (ALT) in the study eye
Prior minimally invasive glaucoma (MIGS) surgery in the study eye
Trial design
Treatments tested in this trial
- Gen 2 Travoprost Intracameral Implant
- Timolol eye drops 0.5%
- Sham Procedure
- placebo eye drops
Treatment groups
510 Participants
are divided into 6 treatment groups6
Treatment groupsSee each treatment group below.
Sponsors and collaborators
Source ClinicalTrials.gov